Payment overview · 2025
General Payments
$278.48
6 reported records · 5 companies
Healthcare provider profile · identity verified
William Coleman Sharp, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHFIELD, MI · NPI 1053312983
Verified facts
What the public records show
CMS Open Payments records show William Coleman Sharp, MD received $278.48 in general payments during 2025 across 6 reported records.
Dexcom, Inc. accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $144.83 | 52.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.86 | 23.3% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $28.70 | 10.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.86 | 8.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.23 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.48 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $144.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.86 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
266 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 135 |
| Simvastatin | Simvastatin | 347 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 100 |
| Allopurinol | Allopurinol | 302 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 78 |
| Metformin Hcl | Metformin Hcl | 291 | 90 |
| Losartan Potassium | Losartan Potassium | 287 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 97 |
| Spironolactone | Spironolactone | 267 | 84 |
| Farxiga | Dapagliflozin Propanediol | 266 | 59 |
| Gabapentin | Gabapentin | 246 | 74 |
| Meloxicam | Meloxicam | 233 | 74 |
| Jardiance | Empagliflozin | 223 | 55 |
| Potassium Chloride | Potassium Chloride | 220 | 60 |
| Carvedilol | Carvedilol | 210 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 45 |
| Trazodone Hcl | Trazodone Hcl | 157 | 44 |
| Famotidine | Famotidine | 151 | 53 |
| Metolazone | Metolazone | 151 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 147 | 47 |
| Montelukast Sodium | Montelukast Sodium | 147 | 43 |
| Eliquis | Apixaban | 145 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 48 |
| Furosemide | Furosemide | 141 | 57 |
| Tramadol Hcl | Tramadol Hcl | 124 | 51 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 123 | 39 |
| Lisinopril | Lisinopril | 120 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 106 | 27 |
| Pregabalin | Pregabalin | 105 | 38 |
| Donepezil Hcl | Donepezil Hcl | 103 | 29 |
| Glimepiride | Glimepiride | 102 | 30 |
| Azithromycin | Azithromycin | 92 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 22 |
| Entresto | Sacubitril/Valsartan | 83 | 21 |
| Januvia | Sitagliptin Phosphate | 80 | 17 |
| Telmisartan | Telmisartan | 80 | 27 |
| Alprazolam | Alprazolam | 79 | 22 |
| Buspirone Hcl | Buspirone Hcl | 79 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 79 | 20 |
| Omeprazole | Omeprazole | 78 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 21 |
| Indapamide | Indapamide | 67 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 66 | 39 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 65 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 18 |
| Xarelto | Rivaroxaban | 65 | 15 |
| Sucralfate | Sucralfate | 64 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 62 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 34 |
| Meclizine Hcl | Meclizine Hcl | 59 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 17 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 54 | 16 |
| Eplerenone | Eplerenone | 50 | 16 |
| Ibuprofen | Ibuprofen | 49 | 18 |
| Temazepam | Temazepam | 49 | 13 |
| Rybelsus | Semaglutide | 48 | 20 |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 47 | 13 |
| Nitroglycerin | Nitroglycerin | 47 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Bumetanide | Bumetanide | 44 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 18 |
| Alendronate Sodium | Alendronate Sodium | 43 | 14 |
| Klor-Con M20 | Potassium Chloride | 43 | 15 |
| Methylprednisolone | Methylprednisolone | 43 | 41 |
| Midodrine Hcl | Midodrine Hcl | 42 | 12 |
| Prednisone | Prednisone | 42 | 19 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 16 |
| Finasteride | Finasteride | 40 | 12 |
| Levetiracetam | Levetiracetam | 38 | 16 |
| Creon | Lipase/Protease/Amylase | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 20 |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 23 |
| Betamethasone Valerate | Betamethasone Valerate | 32 | 11 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | 11 |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | 14 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 13 |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Clonidine | Clonidine | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 11 |
| Diflunisal | Diflunisal | 20 | 12 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Amiloride Hcl | Amiloride Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Cephalexin | Cephalexin | 16 | 15 |
| Lactulose | Lactulose | 16 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.48 · 6 records | Dexcom, Inc. | Assure WCD, BREZTRI, Dexcom G6 Transmitter, Ozempic, Rybelsus, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error